GMP PROTEIN (E. COLI) CONTRACT MANUFACTURING MARKET ANALYSIS

GMP Protein (E. coli) Contract Manufacturing Market, by Product Type (Cytokines, Growth Factors, Enzymes [DNA polymerase, Protease, Trypsin, Nuclease {Benzonase, Cas9 Nucleases, and Others}, IVT Enzymes, and Others] Hormones, Antigens, and Others), by Application (Gene Therapy and Cell Therapy), by Method (In-Vivo and Ex-Vivo), by End User (Biotechnology and Pharmaceutical Companies, Academic & Research Institutes, Contract Research Organizations, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Dec 2022
Code : CMI5433
Pages :603
Formats :
Excel and PDF
Industry : Biotechnology

Market Challenges And Opportunities

Global GMP Protein (E. coli) Contract Manufacturing Market- Drivers

Increasing research and development activities by key market players are expected to drive market growth over the forecast period. For instance, according to Alliance for Regenerative Medicine, 2020, approximately US$ 9.8 billion was raised in global financings for the cell and gene therapy sector in 2019. Moreover, according to the same source, in 2020, there were 572 ongoing regenerative medicine clinical trials in U.S. trial sites.

Increasing inorganic growth strategies by the key players to increase GMP grade protein production capacities is expected to drive market growth over the forecast period. For instance, in October 2021, Avid Bioservices, Inc., a dedicated biologics Contract Development and Manufacturing Organization (CDMO), announced that the company is increasing its CDMO service offering in the rapidly growing cell and gene therapy market. As part of this effort, the company is constructing a world-class, purpose-built 53,000 sq. ft. viral vector development and CGMP manufacturing facility in Costa Mesa, CA, approximately five miles from Avid’s existing operations in Tustin, CA.

Global GMP Protein (E. coli) Contract Manufacturing Market: Restraint

The major factors that hinder the growth of the global GMP protein (E. coli) contract manufacturing market include the high cost of recombinant protein manufacturing. The high cost involved in the production and research and development of recombinant proteins is expected to act as a restraint for the market growth. For instance, according to an article published by MDPI, a publisher of open-access scientific journals, in July 2019, the costs of a single clinical trial can vary from US$ 5 million for small, non-controlled orphan drug trials to US$ 350 million for large controlled studies. The median estimate is US$ 19 million. Moreover, according to an article published by ResearchGate, in July 2019, industrial proteins often have a retail price of tens of dollars per kilogram while recombinant proteins for medical use may cost billions of dollars per kilogram. Thus, the high cost of recombinant protein products and high cost involved in its manufacturing is expected to act as a restraint for the market growth.